MED

Jim Cramer Calls Medtronic (MDT) a “Quandary” as Growth Surges and Diabetes Exit Nears

Exiting Insmed (INSM) Following Disappointing Key Drug Uptake

Johnson & Johnson Eyes High-End MedTech Growth as Cardiovascular Takes Center Stage

There Is No Medicare Appeal When a Medigap Insurer Says No at 72. No Federal Form, No Hearing, Just the Next Company’s Application.

UnitedHealth Slips 3% as TPG Buys Into Florida WellMed Clinics Ahead of Guidance Reaffirmation

Medtronic Is on the Cusp of Becoming a Dividend King. Is the Stock a Buy for Income Investors?

Wall Street Isn't Talking About High-Yield Medtronic Stock -- Here's Why It Should Be

Medicare drug coverage faces an ominous spending outlook

COMIC: If we fight, is our love doomed? And other honest questions about conflict

PVH (PVH) Reaffirmed its Outlook as Tariff Refunds Lifted Margins. Can the Core Business Recover Without the One-Off Benefit?